Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct:59:176-190.
doi: 10.1016/j.jcrc.2020.06.019. Epub 2020 Jul 11.

Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19

Andrea Cortegiani  1 , Mariachiara Ippolito  2 , Giulia Ingoglia  2 , Pasquale Iozzo  3 , Antonino Giarratano  2 , Sharon Einav  4
Affiliations

Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19

Andrea Cortegiani et al. J Crit Care. 2020 Oct.

Abstract

Purpose: To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans.

Materials and methods: MEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched from inception to 8th June 2020 for RCTs and nonrandomized studies (retrospective and prospective, including single-arm, studies) addressing the use of CQ/HCQ in any dose or combination for COVID-19.

Results: Thirty-two studies were included (6 RCTs, 26 nonrandomized, 29,192 participants). Two RCTs had high risk, two 'some concerns' and two low risk of bias (Rob2). Among nonrandomized studies with comparators, nine had high risk and five moderate risk of bias (ROBINS-I). Data synthesis was not possible. Low and moderate risk of bias studies suggest that treatment of hospitalized COVID-19 with CQ/HCQ may not reduce risk of death, compared to standard care. High dose regimens or combination with macrolides may be associated with harm. Postexposure prophylaxis may not reduce the rate of infection but the quality of the evidence is low.

Conclusions: Patients with COVID-19 should be treated with CQ/HCQ only if monitored and within the context of high quality RCTs. High quality data about efficacy/safety are urgently needed.

Keywords: COVID-19; Chloroquine; Hydroxychloroquine; Mortality; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

AC, GI, MI, PI, AG, SE declare to have no competing interests.

Figures

Fig. 1
Fig. 1
Risk of bias of RCTs assessed using Rob2 tool.
Fig. 2
Fig. 2
Risk of bias of nonrandomized studies assessed using ROBINS-I tool.
See this image and copyright information in PMC

References

    1. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. 2020 doi: 10.1001/jama.2020.6019. - DOI - PubMed
    1. Taccone F.S., Gorham J., Vincent J.L. Hydroxychloroquine in the management of critically ill patients with COVID-19: The need for an evidence base. Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30172-7. - DOI - PMC - PubMed
    1. Cortegiani A., Ingoglia G., Ippolito M., Giarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 doi: 10.1016/j.jcrc.2020.03.005. - DOI - PMC - PubMed
    1. Cortegiani A., Ippolito M., Ingoglia G., Einav S. Chloroquine for COVID-19: Rationale, facts, hopes. Crit Care. 2020;24:210. doi: 10.1186/s13054-020-02932-4. - DOI - PMC - PubMed
    1. Reeves B.C., Deeks J.J., Higgins J.P.T., Shea B., PWG Tugwell. Chapter 24: Including non-randomized studies on intervention effects. Cochrane Handb Syst Rev Interv Version 60 (Updated July 2019) Cochrane. 2019 https://training.cochrane.org/handbook/current/chapter-24 (accessed June 9, 2020)

Publication types

MeSH terms